ストックスクリーナーアプリを入手
7.27
2.54%
0.18
アフターアワーズ：
7.27
前日終値:
$7.09
開ける：
$7.14
24時間の取引高:
302.57K
Relative Volume:
0.84
時価総額：
$429.47M
収益：
-
当期純損益:
$-153.16M
株価収益率:
-1.9702
EPS:
-3.69
ネットキャッシュフロー:
$-134.48M
1週間 パフォーマンス:
-10.02%
1か月 パフォーマンス:
-5.58%
6か月 パフォーマンス:
-26.49%
1年 パフォーマンス:
-55.40%
1日の値動き範囲:
$7.0901
$7.40
1週間の範囲:
$6.89
$8.01
52週間の値動き範囲:
$6.85
$19.89
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
CGEM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.27 | 418.84M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 再開されました | Stifel | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-05-01 | 開始されました | Stifel | Buy |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-02-15 | 開始されました | Wedbush | Outperform |
| 2023-06-15 | 開始されました | TD Cowen | Outperform |
| 2022-11-21 | 開始されました | BTIG Research | Buy |
| 2021-04-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 開始されました | Evercore ISI | Outperform |
| 2021-02-02 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 開始されました | SVB Leerink | Outperform |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cullinan Therapeutics Inc (CGEM) 最新ニュース
Is Cullinan Therapeutics Inc. stock poised for growthFree Fundamental Winners With Safe Entry Plan - Newser
Is Cullinan Therapeutics Inc. showing signs of accumulationMonthly Long-Term Market Recap and Summary - Newser
Full technical analysis of Cullinan Therapeutics Inc. stockFree Swing Trade With Risk Management - Newser
Cullinan Therapeutics Inc. stock trend outlook and recovery pathProven Trading System with Consistent Gains - Newser
Market reaction to Cullinan Therapeutics Inc.’s recent newsTechnical Trade Plan with Entry Checklist - Newser
Is Cullinan Therapeutics Inc. stock reversal real or fakeEntry and Exit Strategy for Swing Traders - Newser
How Cullinan Therapeutics Inc. stock performs during market volatilityFree Community Shared Smart Money Signals - Newser
William Blair Has Pessimistic Outlook of CGEM Q3 Earnings - Defense World
Can swing trading help recover from Cullinan Therapeutics Inc. lossesEquity Performance Forecast Based on AI Models - Newser
Key resistance and support levels for Cullinan Therapeutics Inc.Free Value Investing Picks With Stability - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionSector-Wise Stock Strength Trend Analysis - Newser
Cullinan (CGEM) Q2 R&D Jumps 68% - AOL.com
How to track smart money flows in Cullinan Therapeutics Inc.Stock Market Trend and Pattern Analysis - Newser
Using Ichimoku Cloud for Cullinan Therapeutics Inc. technicalsDay Trading Setup and Momentum Analysis - Newser
Cullinan Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Cullinan Therapeutics Reports Q2 2025 Financial Results - TipRanks
What to expect from Cullinan Therapeutics Inc. in the next 30 daysPrice Movement and Market Sentiment Analysis - Newser
Cullinan Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c) - TipRanks
Cullinan Therapeutics Reports Wider-Than-Expected Q2 LossNews and Statistics - IndexBox
Cullinan Therapeutics (CGEM) to Release Earnings on Thursday - Defense World
Cullinan Management Appoints New Board Members - TipRanks
Cullinan Therapeutics Q2 net loss widens to $70.1 mln on higher R&D costs - MarketScreener
Cullinan Therapeutics, Inc. SEC 10-Q Report - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - The Manila Times
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire Inc.
Real time social sentiment graph for Cullinan Therapeutics Inc.Swing Trade Timing with Daily Forecast - Newser
How to manage a losing position in Cullinan Therapeutics Inc.Breakout Monitoring with Momentum Analysis - Newser
Cullinan Therapeutics Inc (CGEM) 財務データ
収益
当期純利益
現金流量
EPS
Cullinan Therapeutics Inc (CGEM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| AHMED NADIM | President and CEO |
Feb 25 '25 |
Sale |
8.53 |
12,529 |
106,872 |
430,621 |
| Michaelson Jennifer | Chief Scientific Officer |
Feb 25 '25 |
Sale |
8.53 |
3,756 |
32,039 |
142,004 |
| SUMER JACQUELYN L | Chief Legal Officer |
Feb 25 '25 |
Sale |
8.53 |
3,756 |
32,039 |
136,895 |
| Michaelson Jennifer | Chief Scientific Officer |
Jan 06 '25 |
Sale |
12.51 |
4,000 |
50,040 |
95,760 |
0.91%
3.06%
大文字化:
|
ボリューム (24 時間):